EUVIMEDEUVIMED entdecken
EditorialKommentarOpen Access

Drug costs: acquisition costs are critical but not the entire story of financial toxicity

Deborah R Kaye

BJU International · 2023

DOI: 10.1111/bju.16092 ↗

Kurz gefasst

Editorial in der Zeitschrift BJU International, 2023. Verfasst von Deborah R Kaye. Beteiligte Einrichtung: Department of Surgery, Duke University, Durham, NC, USA. Hauptthemen laut MEDLINE: Financial Stress, Neoplasms. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 6 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, National Cancer Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Financial StressNeoplasmsHumansCosts and Cost AnalysisHealth ExpendituresCost of IllnessHealth Care Costs

Autor:innen und Institutionen

  • Department of Surgery, Duke University, Durham, NC, USA.
  • Duke-Margolis Center for Public Policy, Duke University, Durham, NC, USA.
  • Duke Clinical Research Institute, Durham, NC, USA.
  • Duke Cancer Institute, Durham, NC, USA.

Förderung

  • NCI NIH HHS
  • National Cancer Institute

Zitieren

APA

Kaye, D. R. (2023). Drug costs: acquisition costs are critical but not the entire story of financial toxicity. BJU International. https://doi.org/10.1111/bju.16092

Vancouver

Kaye DR. Drug costs: acquisition costs are critical but not the entire story of financial toxicity. BJU International. 2023. doi:10.1111/bju.16092

BibTeX
@article{Kaye2023,
  author = {Kaye, Deborah R},
  title = {Drug costs: acquisition costs are critical but not the entire story of financial toxicity},
  journal = {BJU International},
  year = {2023},
  doi = {10.1111/bju.16092}
}
Kostenlos starten →